Jack Stone

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model

Non-alcoholic fatty liver disease – A global public health perspective

Structural racism and health inequities in the USA: evidence and interventions

Burden of liver diseases in the world

Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review

Designing an HCV vaccine: a unique convergence of prevention and therapy?

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Intimate partner violence and receptive syringe sharing among women who inject drugs in Indonesia: A respondent-driven sampling study

Direct-acting antiviral agents for HCV infection affecting people who inject drugs

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine

Global burden of liver disease: 2023 update

Mass incarceration, public health, and widening inequality in the USA

Hepatitis C Virus: 30 Years after Its Discovery

Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies

Challenges and Promise of a Hepatitis C Virus Vaccine

Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study

The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs

Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Sexually Transmitted Infections Treatment Guidelines, 2021

The Effect of Intimate Partner Violence on the Physical Health and Health-Related Behaviors of Women: A Systematic Review of the Literature

Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

EASL Recommendations on Treatment of Hepatitis C 2018

Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response

Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia

Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison

Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs